Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

1,300 Days and Counting: A Risk Model Approach to Preventing Retained Foreign Objects (RFOs).

Duggan EG, Fernandez J, Saulan MM, Mayers DL, Nikolaj M, Strah TM, Swift LM, Temple L.

Jt Comm J Qual Patient Saf. 2018 May;44(5):260-269. doi: 10.1016/j.jcjq.2017.11.006.

PMID:
29759259
2.

Ebola virus disease: an update on post-exposure prophylaxis.

Fischer WA 2nd, Vetter P, Bausch DG, Burgess T, Davey RT Jr, Fowler R, Hayden FG, Jahrling PB, Kalil AC, Mayers DL, Mehta AK, Uyeki TM, Jacobs M.

Lancet Infect Dis. 2018 Jun;18(6):e183-e192. doi: 10.1016/S1473-3099(17)30677-1. Epub 2017 Nov 15. Review.

3.

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys.

Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR, Flint M, McMullan LK, Chen SS, Fearns R, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S.

Nature. 2016 Mar 17;531(7594):381-5. doi: 10.1038/nature17180. Epub 2016 Mar 2. Erratum in: ACS Chem Biol. 2016 May 20;11(5):1463.

4.

Current status of chemically synthesized inhibitors of Ebola virus.

Cardile AP, Mayers DL, Bavari S.

Recent Pat Antiinfect Drug Discov. 2014;9(2):97-103. Review.

PMID:
25808170
5.

Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design.

Boltz VF, Maldarelli F, Martinson N, Morris L, McIntyre JA, Gray G, Hopley MJ, Kimura T, Mayers DL, Robinson P, Mellors JW, Coffin JM, Palmer SE.

J Virol Methods. 2010 Mar;164(1-2):122-6. doi: 10.1016/j.jviromet.2009.11.025. Epub 2009 Dec 3.

6.

Population pharmacokinetics of telbivudine and determination of dose adjustment for patients with renal impairment.

Zhou XJ, Ke J, Sallas WM, Farrell C, Mayers DL, Pentikis HS.

J Clin Pharmacol. 2009 Jun;49(6):725-34. doi: 10.1177/0091270009333555. Epub 2009 Apr 24.

PMID:
19395586
7.

Seeking ethical designs for HIV clinical trials in treatment-experienced patients: an industry perspective.

Mayers DL, Chung J, Kohlbrenner VM, Hall DB, DeMasi RA, Neubacher D, Buss NE, Salgo MP.

AIDS Res Hum Retroviruses. 2006 Nov;22(11):1110-2. No abstract available.

PMID:
17147497
8.

Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study.

Lawrence J, Hullsiek KH, Thackeray LM, Abrams DI, Crane LR, Mayers DL, Jones MC, Saldanha JM, Schmetter BS, Baxter JD.

J Acquir Immune Defic Syndr. 2006 Oct 1;43(2):169-78.

PMID:
16951642
9.

Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.

Baxter JD, Schapiro JM, Boucher CA, Kohlbrenner VM, Hall DB, Scherer JR, Mayers DL.

J Virol. 2006 Nov;80(21):10794-801. Epub 2006 Aug 23.

10.

A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients.

McCallister S, Valdez H, Curry K, MacGregor T, Borin M, Freimuth W, Wang Y, Mayers DL.

J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):376-82.

PMID:
15097154
11.

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients.

Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL.

J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S21-33.

PMID:
14562855
12.

Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.

Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, Crane LR, Schmetter BS, Dionne TJ, Saldanha JM, Jones MC, Baxter JD; 064 Study Team of the Terry Beirn Community Programs for Clinical Research on AIDS.

N Engl J Med. 2003 Aug 28;349(9):837-46.

13.

The lack of therapeutic benefit of adding hydroxyurea to highly active antiretroviral therapy (HAART).

Gonzalez OY, Jovanovich JF, Mayers DL, Musher DM.

J Acquir Immune Defic Syndr. 2002 Jul 1;30(3):363-4. No abstract available.

PMID:
12131575
14.

Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus.

Holland-Staley CA, Kovari LC, Golenberg EM, Pobursky KJ, Mayers DL.

Arch Virol. 2002 Jul;147(7):1385-406.

PMID:
12111414
15.

Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy.

Baxter JD, Merigan TC, Wentworth DN, Neaton JD, Hoover ML, Hoetelmans RM, Piscitelli SC, Verbiest WH, Mayers DL; CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

AIDS. 2002 May 24;16(8):1131-8.

PMID:
12004271
16.

Genotypic drug resistance and cause of death in HIV-infected persons who died in 1999.

Beinker NK, Mayers DL, Lange CG, Valdez H, Sitkins J, Lemonnier L, Chowdhry TK, Lederman MM.

J Acquir Immune Defic Syndr. 2001 Nov 1;28(3):250-3.

PMID:
11694831
17.

The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial.

MacArthur RD, Chen L, Mayers DL, Besch CL, Novak R, van den Berg-Wolf M, Yurik T, Peng G, Schmetter B, Brizz B, Abrams D; CPCRA 058 FIRST Trial Study Team.

Control Clin Trials. 2001 Apr;22(2):176-90.

PMID:
11306155
18.

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC.

AIDS. 2000 Jun 16;14(9):F83-93.

PMID:
10894268
19.

Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS.

Winters MA, Baxter JD, Mayers DL, Wentworth DN, Hoover ML, Neaton JD, Merigan TC.

Antivir Ther. 2000 Mar;5(1):57-63.

PMID:
10846594
20.

Primary lamivudine resistance in acute/early human immunodeficiency virus infection.

Conway B, Montessori V, Rouleau D, Montaner JS, O'Shaughnessy MV, Fransen S, Shillington A, Weislow O, Mayers DL.

Clin Infect Dis. 1999 Apr;28(4):910-1. No abstract available.

PMID:
10825060
21.

Stavudine-induced macrocytosis during therapy for human immunodeficiency virus infection.

Martin GJ, Blazes DL, Mayers DL, Spooner KM.

Clin Infect Dis. 1999 Aug;29(2):459-60. No abstract available.

PMID:
10476771
22.

Exotic virus infections of military significance. Hemorrhagic fever viruses and pox virus infections.

Mayers DL.

Dermatol Clin. 1999 Jan;17(1):29-40, vii-viii. Review.

PMID:
9986994
23.

Drug-resistant HIV-1: the virus strikes back.

Mayers DL.

JAMA. 1998 Jun 24;279(24):2000-2. No abstract available.

PMID:
9643867
24.

Size and duration of zidovudine benefit in 1003 HIV-infected patients: U.S. Army, Navy, and Air Force natural history data. Military Medical Consortium for Applied Retroviral Research.

Gardner LI, Harrison SH, Hendrix CW, Blatt SP, Wagner KF, Chung RC, Harris RW, Cohn DL, Burke DS, Mayers DL.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):345-53.

PMID:
9525436
25.

Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs.

Mayers DL.

Am J Med. 1997 May 19;102(5B):70-5. Review.

PMID:
9845501
26.
27.

Evolution of human immunodeficiency virus type 1 env sequence variation in patients with diverse rates of disease progression and T-cell function.

McDonald RA, Mayers DL, Chung RC, Wagner KF, Ratto-Kim S, Birx DL, Michael NL.

J Virol. 1997 Mar;71(3):1871-9.

28.

Measurement of CD69 induction in the assessment of immune function in asymptomatic HIV-infected individuals.

Perfetto SP, Hickey TE, Blair PJ, Maino VC, Wagner KF, Zhou S, Mayers DL, St Louis D, June CH, Siegel JN.

Cytometry. 1997 Feb 15;30(1):1-9.

PMID:
9056736
29.

AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay.

Sharma PL, Chatis PA, Dogon AL, Mayers DL, McCutchan FE, Page C, Crumpacker CS.

Virology. 1996 Sep 15;223(2):365-9. Erratum in: Virology 1996 Nov 15;225(2):428.

30.

Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical Trials Group Virology Committee Drug Resistance Working Group.

Shafer RW, Winters MA, Mayers DL, Japour AJ, Kuritzkes DR, Weislow OS, White F, Erice A, Sannerud KJ, Iversen A, Pena F, Dimitrov D, Frenkel LM, Reichelderfer PS.

J Clin Microbiol. 1996 Jul;34(7):1849-53.

31.

Exposure of human CD34+ cells to human immunodeficiency virus type 1 does not influence their expansion and proliferation of hematopoietic progenitors in vitro.

Kaushal S, La Russa VF, Gartner S, Kessler S, Perfetto S, Yu Z, Ritchey DW, Xu J, Perera P, Kim J, Reid T, Mayers DL, St Louis D, Mosca JD.

Blood. 1996 Jul 1;88(1):130-7.

32.

Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation.

Levine BL, Mosca JD, Riley JL, Carroll RG, Vahey MT, Jagodzinski LL, Wagner KF, Mayers DL, Burke DS, Weislow OS, St Louis DC, June CH.

Science. 1996 Jun 28;272(5270):1939-43.

PMID:
8658167
33.

Intact antigen receptor-mediated calcium signals in patients with early stage HIV-1 infection.

Hickey TE, Blair PJ, Perfetto S, Smoot DS, Wagner KF, St Louis DC, Mayers DL, Siegel JN, June CH.

J Immunol. 1996 May 15;156(10):4012-7.

PMID:
8621943
34.

Antihuman Immunodeficiency Virus (HIV-1) Activities of Inhibitors of Polyamine Pathways.

Chiang PK, McCann PP, Lane JR, Pankaskie MC, Burke DS, Mayers DL.

J Biomed Sci. 1996 Apr;3(2):78-81.

PMID:
11725087
35.

Characterization of a Human Stromal Cell Line Supporting Hematopoietic Progenitor Cell Proliferation: Effect of HIV Expression.

Mosca JD, Kaushal S, Gartner S, Kessler SW, La Russa VF, Terwilliger EF, Kim JH, Carroll RG, Hall ER, Perera LP, Yu Z, Ritchey DW, Xu J, St Louis DC, Mayers DL.

J Biomed Sci. 1995 Oct;2(4):330-342.

PMID:
11725070
36.
37.

Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase.

Buckheit RW Jr, Fliakas-Boltz V, Yeagy-Bargo S, Weislow O, Mayers DL, Boyer PL, Hughes SH, Pan BC, Chu SH, Bader JP.

Virology. 1995 Jun 20;210(1):186-93.

38.

Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates.

Mellors JW, Bazmi HZ, Schinazi RF, Roy BM, Hsiou Y, Arnold E, Weir J, Mayers DL.

Antimicrob Agents Chemother. 1995 May;39(5):1087-92.

39.

Assays for antiviral drug resistance.

Kimberlin DW, Spector SA, Hill EL, Biron KK, Hay AJ, Mayers DL, Whitley RJ.

Antiviral Res. 1995 Apr;26(4):403-13. Review. No abstract available.

PMID:
7574542
40.

Anti-human immunodeficiency virus 1 (HIV-1) activities of 3-deazaadenosine analogs: increased potency against 3'-azido-3'-deoxythymidine-resistant HIV-1 strains.

Mayers DL, Mikovits JA, Joshi B, Hewlett IK, Estrada JS, Wolfe AD, Garcia GE, Doctor BP, Burke DS, Gordon RK, et al.

Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):215-9.

41.

Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates.

Japour AJ, Fiscus SA, Arduino JM, Mayers DL, Reichelderfer PS, Kuritzkes DR.

J Clin Microbiol. 1994 Sep;32(9):2291-4.

42.

Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.

Mayers DL, Japour AJ, Arduino JM, Hammer SM, Reichman R, Wagner KF, Chung R, Lane J, Crumpacker CS, McLeod GX, et al.

Antimicrob Agents Chemother. 1994 Feb;38(2):307-14.

43.

Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group.

Japour AJ, Mayers DL, Johnson VA, Kuritzkes DR, Beckett LA, Arduino JM, Lane J, Black RJ, Reichelderfer PS, D'Aquila RT, et al.

Antimicrob Agents Chemother. 1993 May;37(5):1095-101.

44.

Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1.

Erice A, Mayers DL, Strike DG, Sannerud KJ, McCutchan FE, Henry K, Balfour HH Jr.

N Engl J Med. 1993 Apr 22;328(16):1163-5. No abstract available.

45.

CD4 lymphocyte counts within 24 months of human immunodeficiency virus seroconversion. Findings in the US Navy and Marine Corps. The Navy Retroviral Working Group.

Gorham ED, Garland FC, Mayers DL, Goforth RR, Brodine SK, Wiess PJ, McNally MS.

Arch Intern Med. 1993 Apr 12;153(7):869-76.

PMID:
8096691
46.

Hospital-acquired wound mucormycosis.

Paparello SF, Parry RL, MacGillivray DC, Brock N, Mayers DL.

Clin Infect Dis. 1992 Jan;14(1):350-2.

PMID:
1571450
47.

Characterization of HIV isolates arising after prolonged zidovudine therapy.

Mayers DL, McCutchan FE, Sanders-Buell EE, Merritt LI, Dilworth S, Fowler AK, Marks CA, Ruiz NM, Richman DD, Roberts CR, et al.

J Acquir Immune Defic Syndr. 1992;5(8):749-59.

PMID:
1381438
48.

Xenon kinetics in muscle are not explained by a model of parallel perfusion-limited compartments.

Novotny JA, Mayers DL, Parsons YF, Survanshi SS, Weathersby PK, Homer LD.

J Appl Physiol (1985). 1990 Mar;68(3):876-90.

PMID:
2341354
49.

An updated therapeutic review. Zidovudine.

Brouker ME, Donegan SE, Karney WW, Mayers DL.

Navy Med. 1990 Jan-Feb;81(1):26-8. No abstract available.

PMID:
2370912
50.

Incidence of human immunodeficiency virus seroconversion in US Navy and Marine Corps personnel, 1986 through 1988.

Garland FC, Mayers DL, Hickey TM, Miller MR, Shaw EK, Gorham ED, Bigbee LR, McNally MM.

JAMA. 1989 Dec 8;262(22):3161-5.

PMID:
2810674

Supplemental Content

Loading ...
Support Center